Abstract
3BNC117 is a broad and potent neutralizing antibody to HIV-1 that targets the CD4 binding site on the viral envelope spike. When administered passively, this antibody can prevent infection in animal models and suppress viremia in HIV-1-infected individuals. Here we report that HIV-1 immunotherapy with a single injection of 3BNC117 affects host antibody responses in viremic individuals. In comparison to untreated controls that showed little change in their neutralizing activity over a 6-month period, 3BNC117 infusion significantly improved neutralizing responses to heterologous tier 2 viruses in nearly all study participants. We conclude that 3BNC117-mediated immunotherapy enhances host humoral immunity to HIV-1.
Trial registration:
ClinicalTrials.gov NCT02018510.
Copyright © 2016, American Association for the Advancement of Science.
Publication types
-
Clinical Trial, Phase I
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Amino Acid Sequence
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Humanized
-
Antibodies, Neutralizing / administration & dosage
-
Antibodies, Neutralizing / therapeutic use*
-
Antibody Formation
-
Broadly Neutralizing Antibodies
-
Female
-
HIV Antibodies / administration & dosage
-
HIV Antibodies / therapeutic use*
-
HIV Infections / immunology
-
HIV Infections / therapy*
-
HIV-1 / classification
-
HIV-1 / genetics
-
HIV-1 / immunology*
-
Humans
-
Immunity, Humoral
-
Immunization, Passive / methods*
-
Male
-
Middle Aged
-
Phylogeny
-
Viremia / immunology
-
Viremia / therapy*
-
Young Adult
Substances
-
3BNC117 antibody
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antibodies, Neutralizing
-
Broadly Neutralizing Antibodies
-
HIV Antibodies
Associated data
-
ClinicalTrials.gov/NCT02018510